Halozyme

Halozyme Acquires Drug Delivery Company Elektrofi

Halozyme has acquired Elektrofi to expand its drug delivery portfolio, with royalty revenues expected to start by 2030 as partnered products advance to clinical development.

Top-Feature

Nova-Institut GmbH

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Free Expert Insights

Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Halozyme

Halozyme Acquires Drug Delivery Company Elektrofi

Top-Feature

Advanced Recycling Conference 2025: New Paths to the Circular Economy

20 Years of CHEManager International

Brenntag Downsizes Management Board, Retains Both Divisions

A successful concept on course for expansion — maintenance Munich 2025

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Free Expert Insights

Dual‑Targeting Breakthroughs

Newsletter & e-edition